Details of the Drug

General Information of Drug (ID: DMDY08K)

Drug Name

GDC-0623

Synonyms

1168091-68-6; GDC 0623; UNII-HW67545I4Q; RG 7421; GDC0623; HW67545I4Q; G-868; Imidazo[1,5-a]pyridine-6-carboxamide, 5-[(2-fluoro-4-iodophenyl)amino]-N-(2-hydroxyethoxy)-; 5-((2-FLUORO-4-IODOPHENYL)AMINO)-N-(2-HYDROXYETHOXY)IMIDAZO[1,5-A]PYRIDINE-6-CARBOXAMIDE; RFWVETIZUQEJEF-UHFFFAOYSA-N; GTPL9909; SCHEMBL1615104; CHEMBL3330650; MolPort-039-193-834; BCP28689; AOB87143; EX-A2060; s7553; ZINC43206499; BDBM50025226; AKOS027253679; DB11982; SB16957; CS-2281; BC600628; HY-15610; KB-144448; FT-0769207; Z-3311

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

456.21

Topological Polar Surface Area (xlogp)

3.7

Rotatable Bond Count (rotbonds)

6

Hydrogen Bond Donor Count (hbonddonor)

3

Hydrogen Bond Acceptor Count (hbondacc)

6

Chemical Identifiers

Formula: C16H14FIN4O3
IUPAC Name: 5-(2-fluoro-4-iodoanilino)-N-(2-hydroxyethoxy)imidazo[1,5-a]pyridine-6-carboxamide
Canonical SMILES: C1=CC(=C(C=C1I)F)NC2=C(C=CC3=CN=CN32)C(=O)NOCCO
InChI: InChI=1S/C16H14FIN4O3/c17-13-7-10(18)1-4-14(13)20-15-12(16(24)21-25-6-5-23)3-2-11-8-19-9-22(11)15/h1-4,7-9,20,23H,5-6H2,(H,21,24)
InChIKey: RFWVETIZUQEJEF-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 42642654
CAS Number: 1168091-68-6
DrugBank ID: DB11982
TTD ID: D0R3VK

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
ERK activator kinase (MEK)	TTZCRP3	NOUNIPROTAC	Inhibitor	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Clinical pipeline report, company report or official report of Genentech (2011).
2	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
3	Current Development Status of MEK Inhibitors. Molecules. 2017 Sep 26;22(10):1551.
4	Clinical pipeline report, company report or official report of Roche.
5	Clinical pipeline report, company report or official report of Boehringer Ingelheim.
6	MEK inhibitors in oncology: a patent review (2015-Present).Expert Opin Ther Pat. 2017 Aug;27(8):887-906.